Martin Reck

German Center for Lung Research — Germany

Medicine · Health Sciences

88h-index52.5kcitations626works10.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(437), Lung Cancer Diagnosis and Treatment(173), Lung Cancer Research Studies(173), Cancer Immunotherapy and Biomarkers(168), Colorectal Cancer Treatments and Studies(84)

Publications620 total

Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
Lung Cancer Targets and Therapy·2026Open Access
Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design
Future Oncology·2025· 1 citedOpen Access
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations
Nature Communications·2025· 2 citedOpen Access
Supplementary Data from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
2025Open Access
Erratum: Whitepaper zu Identifikation, Information und Eignungsprüfung von potenziellen Teilnehmern an der Lungenkrebsfrüherkennung in Deutschland
Pneumologie·2025Open Access
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study
The Lancet Oncology·2025· 1 citedOpen Access
Low E-Cadherin Expression is Associated with Poor Prognosis in Pulmonal Adenocarcinoma
2025Open Access
Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671
The Annals of Thoracic Surgery·2025
High GLUT1 protein expression is associated with unfavorable tumor features and poor prognosis in non-small cell lung cancer
Translational Lung Cancer Research·2025Open Access
417P Benchmarking digital pathology foundation models on PD-L1 slides for immunotherapy response classification
ESMO Real World Data and Digital Oncology·2025Open Access
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults
Lung Cancer·2025· 1 citedOpen Access
Whitepaper zu Identifikation, Information und Eignungsprüfung von potenziellen Teilnehmern an der Lungenkrebsfrüherkennung in Deutschland
Pneumologie·2025· 1 citedOpen Access
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
Nature Reviews Clinical Oncology·2025· 1 cited
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
Journal of Thoracic Oncology·2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
Journal of Thoracic Oncology·2025
Corrigendum to “Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]
JTO Clinical and Research Reports·2025Open Access
LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671
Annals of Oncology·2025Open Access
Interpreting immunogenicity in oncology clinical trials
Cancer Treatment Reviews·2025Open Access
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Nature Reviews Clinical Oncology·2025· 8 cited
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials
Journal of Thoracic Oncology·2025· 3 cited
page 1 of 31Next →

Frequent Co-authors

Solange Peters(17), Enriqueta Felip(15), Luis Paz‐Ares(14), Tony Mok(14), Silvia Novello(13), Fabrice Barlési(13), Mark A. Socinski(10), Delvys Rodríguez‐Abreu(9), Kenneth J. O’Byrne(9), Keith M. Kerr(9), Egbert F. Smit(9), Corinne Faivre‐Finn(8), Rolf A. Stahel(8), Suresh S. Ramalingam(7), Julie R. Brahmer(7), Suresh Senan(7), Makoto Nishio(7), Benjamin Besse(7), Robert M. Jotte(6), Federico Cappuzzo(6)